Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.yjmcc.2020.08.017 http://scihub22266oqcxt.onion/10.1016/j.yjmcc.2020.08.017 32891636!7470794!32891636     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Mol+Cell+Cardiol 2020 ; 148 (ä): 46-49 Nephropedia Template TP {{tp|p=32891636|t=2020. MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes |pdf=|usr=}}{{32891636}} gab.com Text MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes JO: J Mol Cell Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=32891636 #FOAvip The World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) as a public health emergency of international concern as more than 15 million cases were reported by 24th July 2020. Angiotensin-converting enzyme 2 (ACE2) is a COVID-19 entry receptor regulating host cell infection. A recent study reported that ACE2 is expressed in cardiomyocytes. In this study, we aimed to explore if there are microRNA (miRNA) molecules which target ACE2 and which may be exploited to regulate the SARS-CoV-2 receptor. Our data reveal that both Ace2 mRNA and Ace2 protein levels are inhibited by miR-200c in rat primary cardiomyocytes and importantly, in human iPSC-derived cardiomyocytes. We report the first miRNA candidate that can target ACE2 in cardiomyocytes and thus may be exploited as a preventive strategy to treat cardiovascular complications of COVID-19. Twit Text FOAVip MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes ????J Mol Cell Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=32891636 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32891636 #FOAvip English Wikipedia <ref>{{Cite pmid|32891636}}</ref> MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes #MMPMID32891636 Lu D; Chatterjee S; Xiao K; Riedel I; Wang Y; Foo R; Bar C; Thum T J Mol Cell Cardiol 2020[Nov]; 148 (ä): 46-49 PMID32891636show ga The World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) as a public health emergency of international concern as more than 15 million cases were reported by 24th July 2020. Angiotensin-converting enzyme 2 (ACE2) is a COVID-19 entry receptor regulating host cell infection. A recent study reported that ACE2 is expressed in cardiomyocytes. In this study, we aimed to explore if there are microRNA (miRNA) molecules which target ACE2 and which may be exploited to regulate the SARS-CoV-2 receptor. Our data reveal that both Ace2 mRNA and Ace2 protein levels are inhibited by miR-200c in rat primary cardiomyocytes and importantly, in human iPSC-derived cardiomyocytes. We report the first miRNA candidate that can target ACE2 in cardiomyocytes and thus may be exploited as a preventive strategy to treat cardiovascular complications of COVID-19. |Angiotensin-Converting Enzyme 2/*genetics[MESH] |Animals[MESH] |COVID-19/*genetics/virology[MESH] |Cells, Cultured[MESH] |Computer Simulation[MESH] |Fibroblasts/metabolism[MESH] |Human Umbilical Vein Endothelial Cells[MESH] |Humans[MESH] |Induced Pluripotent Stem Cells/cytology[MESH] |Mice[MESH] |MicroRNAs/*genetics[MESH] |Myocardium/*metabolism[MESH] |Myocytes, Cardiac/*metabolism/virology[MESH] |Rats[MESH] |Real-Time Polymerase Chain Reaction[MESH]MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocyt(epmc).pdf DeepDyve Pubget Overpricing